Tango Therapeutics, Inc. (TNGX) News
Track canonical SquawkNews coverage tagged to TNGX, Tango Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
TNGX: Vopimetostat delivers breakthrough efficacy in cancer, with pivotal data and regulatory updates ahead
Vopimetostat, a PRMT5 inhibitor, has shown unprecedented response rates in pancreatic cancer and is advancing toward regulatory approval, with a strong focus on combination therapies and expansion into lung cancer and gl
EQUITY | Sep 09, 2026, 02:14 PM UTC
M
TNGX’s vopimetostat PRMT5 inhibitor expands into lung and brain tumors
TNGX said vopimetostat, a PRMT5 inhibitor, is advancing toward approval and expanding beyond pancreatic cancer into lung cancer and glioblastoma, with additional data updates expected at ESMO.
EQUITY | Sep 09, 2026, 01:42 PM UTC
L
Tango Therapeutics announces Nasdaq Rule 5635(c)(4) inducement grants
Tango Therapeutics (TNGX) announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
Tango Therapeutics grants 146,500-share non-qualified stock option
Tango Therapeutics said its Compensation Committee granted a non-qualified stock option to purchase 146,500 shares, effective September 1, 2026.
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
Tango Therapeutics management set for Cantor Global Healthcare fireside chat Sept. 9
Tango Therapeutics (TNGX) said members of its management team are scheduled for a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026.
EQUITY | Sep 01, 2026, 11:07 AM UTC
L
TNGX - Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
TNGX - Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
EQUITY | Sep 01, 2026, 11:00 AM UTC
M
TNGX Files Prospectus For $400M Common Stock
Tango Therapeutics files prospectus for up to $400M common stock offering
EQUITY | Aug 11, 2026, 09:14 PM UTC
L
TNGX PT raised from $36 to $40, maintains Outperform @ Mizuho
TNGX PT raised from $36 to $40, maintains Outperform @ Mizuho
EQUITY | Jul 17, 2026, 11:25 AM UTC
L
TNGX Initiated Overweight W/$46.00 PT at JPMorgan
TNGX Initiated Overweight W/$46.00 PT at JPMorgan
EQUITY | Jul 15, 2026, 11:47 AM UTC
L
TNGX new Overweight W/ $46 PT @ JPMC
TNGX new Overweight W/ $46 PT @ JPMC
EQUITY | Jul 15, 2026, 11:22 AM UTC